Schizophrenia: Molecular Markers of Disease Progression

精神分裂症：疾病进展的分子标志物

• 批准号: 6824570
• 负责人: ELIZABETH A THOMAS
• 金额: $ 35.05万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2009-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6824570
• 关键词: antipsychotic agents; brain; clinical research; clozapine; gene expression; gene expression profiling; haloperidol; high throughput technology; human tissue; in situ hybridization; neurogenetics; pathologic process; pharmacogenetics; polymerase chain reaction; postmortem; prefrontal lobe /cortex; schizophrenia; temporal lobe /cortex; western blottings

DESCRIPTION (provided by applicant): Schizophrenia is a life-long mental illness with variable expression and unknown etiology. The major clinical manifestations of schizophrenia at disease onset are psychotic symptoms; however, as the illness progresses the negative symptoms become more predominant. In addition, many other neurological aspects change over the course of illness. The molecular factors that influence symptom presentation and the course of schizophrenia after its onset and how treatment modifies the effects of illness remain important and essentially unaddressed questions. Our goals in this application are to identify genes that have altered levels of expression in the CNS of individual subjects who have had a short or long duration of illness using the automate method Total Gene expression Analysis (TOGA*/R). We will generate gene expression profiles from the prefrontal and temporal cortices of individual schizophrenic subjects at different stages of illness: 10 acute schizophrenic subjects (illness duration <5 yrs), 10 chronic schizophrenic subjects (illness duration >22 yrs) and 20 controls, age- and sex- matched to both disease cohorts (n=80 expression profiles total). Since correct treatment early in the illness is thought to have a beneficial affect on the outcome of the disease, the identification of genes involved in the early versus late stages of disease will be important for understanding disease progression. We will also investigate disease heterogeneity in the schizophrenia syndrome by distinguishing gene expression patterns that are present in subsets of all schizophrenic individuals. We will further characterize how the expression of antipsychotic drug-regulated genes (previously identified in mice) is altered in human subjects with schizophrenia in order to elucidate potential consequences of antipsychotic drug exposure in humans. This will be accomplished by measuring expression differences of candidate genes in postmortem brain samples from chronic schizophrenic subjects by real-time PCR, in situ hybridization and Western blot analyses. Overall, these studies may lead to approaches that will favorably alter the course, treatment and outcome of schizophrenia.

描述（由申请人提供）：精神分裂症是一种表达多变、病因不明的终身精神疾病。精神分裂症发病时的主要临床表现为精神病性症状；然而，随着病情的发展，阴性症状变得更加明显。此外，许多其他的神经方面也会随着疾病的发展而改变。影响精神分裂症发病后症状表现和病程的分子因素，以及治疗如何改变疾病的影响，仍然是重要且基本上未解决的问题。在这个应用程序中，我们的目标是使用自动化方法总基因表达分析（TOGA*/R）识别在患有短期或长期疾病的个体受试者的中枢神经系统中改变表达水平的基因。我们将从处于不同疾病阶段的个体精神分裂症受试者的前额叶和颞叶皮层中生成基因表达谱：10名急性精神分裂症受试者（病程<5年），10名慢性精神分裂症受试者（病程bbb22年）和20名对照，年龄和性别与两个疾病队列相匹配（n=80个表达谱）。由于在疾病早期进行正确的治疗被认为对疾病的结果有有益的影响，因此鉴定与疾病早期和晚期阶段有关的基因对于了解疾病进展将是重要的。我们还将通过区分所有精神分裂症个体亚群中存在的基因表达模式来研究精神分裂症综合征的疾病异质性。我们将进一步描述抗精神病药物调节基因（先前在小鼠中发现）在精神分裂症患者中的表达是如何改变的，以阐明人类抗精神病药物暴露的潜在后果。这将通过实时PCR、原位杂交和Western blot分析来测量慢性精神分裂症受试者死后脑样本中候选基因的表达差异来完成。总的来说，这些研究可能会带来有利于改变精神分裂症病程、治疗和结果的方法。